Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerations

Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerations - Luxturna® Follow Up

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50929

Enrollment

Registered

2021-01-26

Start date

2021-03-15

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RPE65-associated inherited retinal degenerations

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Scheduled to receive treatment with Luxturna® Informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Full-field stimulus testing (FST) at 1 year.	—

Secondary

Measure	Time frame
Visual acuity Visual field Mobility course	—

Countries

Netherlands

Outcome results